On September 17, 2026, the California State Board of Pharmacy posted a Notice of Modified Text for its rulemaking under 16 CCR Section 1749, the fee schedule that funds the Board's licensing and oversight of every pharmacy operating in the state. The move opens a 15-day public comment period running through October 2, 2026, and puts the modified fee table on track to take effect July 1, 2027.
The Board approved the modifications at its September 17 meeting, trimming its original proposal while still raising key license fees. Pharmacy permit issuance rises from $750 to $1,250, down from the $2,000 first proposed in March 2026, and the nonresident sterile compounding pharmacy renewal fee climbs to $15,000, nearly double its current level. These are the last amounts stakeholders can move before adoption.
What fees change under the modified 1749 text?
The modified text amends the fee schedule in 16 CCR 1749, which sets the charges the Board levies on California-licensed pharmacies, nonresident pharmacies, and sterile compounding facilities. Two moves dominate. The pharmacy permit issuance fee increases from $750 to $1,250, a $500 jump that the Board scaled back from the $2,000 it originally noticed. The nonresident sterile compounding pharmacy renewal fee rises to $15,000, close to twice its prior rate, reflecting the heavier inspection and oversight burden the Board assigns to out-of-state sterile compounders that ship into California.
Because this is modified text, only the changed provisions are open in the 15-day window; parties cannot relitigate sections the Board left untouched. Written comments must reach the Board by 5:00 p.m. Pacific on October 2, 2026.
Who must act, and by when?
Every California Board of Pharmacy licensee class is in scope: community and hospital pharmacies, chain operators such as CVS, Walgreens, and Kaiser Permanente, Amazon Pharmacy, independent stores, wholesalers and third-party logistics providers, plus nonresident sterile compounding and outsourcing facilities that sell into California. The 15-day window closes October 2, 2026, after which the Board can adopt the text and file it with the Department of Consumer Affairs for final review.
The new fees apply beginning July 1, 2027, the Board's standard fiscal-year start. Licensees renewing on or after that date pay the updated amounts, so 2027-2028 renewal budgets should reflect them now.
| Milestone | Date |
|---|---|
| Board approved proposed text | March 18, 2026 |
| 45-day comment period | July 31 to September 14, 2026 |
| Board approved modifications; Notice of Modified Text posted | September 17, 2026 |
| 15-day comment period on modified text | September 17 to October 2, 2026 |
| New fee schedule effective | July 1, 2027 |
What about the parallel central-fill rulemaking?
The same index update reopened a companion file: the rulemaking to add 16 CCR Section 1707.4 on central fill pharmacies, listed on the Board's pending regulations page. The Board adopted that regulation on April 29, 2026, but it had been sitting in final rulemaking file review at the Department of Consumer Affairs. A Notice of Second Modified Text now restarts the clock, opening a separate 15-day comment period from September 18 to October 2, 2026. It is a distinct file, not a second chance to challenge the 1749 fees.
For operators of central-fill or mail-order fulfillment, section 1707.4 sets the conditions under which a pharmacy can fill and deliver another pharmacy's prescriptions; the second modified text is the last opening to shape those conditions before the rule is filed as final.
Continuous, per-jurisdiction real-time monitoring surfaces fee and rulemaking changes like this the moment the Board posts them, so licensing teams catch the budget impact before the renewal cycle arrives.
Subscribe to the free newsletter
Compliance leads should act on three fronts now. Verify whether your facility holds a California pharmacy permit, a nonresident pharmacy license, or a nonresident sterile compounding registration, and map each to the affected fee line. Quantify the 2027-2028 budget delta: a single sterile compounding renewal moving to $15,000, plus issuance at $1,250 per new permit, can shift multi-site cost projections materially. File written comments on the modified text by October 2, 2026, and track the 1707.4 central-fill window that closes the same day. Obsidian follows California pharmacy fee and rulemaking developments as they publish, so teams can act on the text rather than discover it at renewal.
